ابحث في العناوين
4
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Business News ·
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
Business News ·
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Business News ·
A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compar
All Top News -- ScienceDaily ·